Biomarkers in multiple sclerosis.

Clin Immunol
Authors
Keywords
Abstract

Substantial effort has been made over the last six decades to identify biomarkers for multiple sclerosis that can improve disease diagnosis, predict disease progression, and improve clinical outcomes. However, to date, few of these findings have proven clinically useful. In this review, we address the current state of MS biomarker research. We start by discussing biomarkers currently in clinical use including Oligoclonal bands, MRI, and JC viral titers. We go on to discuss other potential biomarkers from MS serum and cerebrospinal fluid including Markers of neurodegeneration including neurofilament and GFAP, the monocyte macrophage marker CD163, the glial activation marker YKL-40, the B cell chemoattractant CXCL13, miRNA and mRNA, myelin reactive t cells, Kir4.1 antibodies, osteopontin, and microbiome associated lipopeptides. Finally, we discuss the current state of MS genetic studies and how genetics may offer simple, reliable testing for MS susceptibility and progression.

Year of Publication
2015
Journal
Clin Immunol
Volume
161
Issue
1
Pages
51-8
Date Published
2015 Nov
ISSN
1521-7035
URL
DOI
10.1016/j.clim.2015.06.015
PubMed ID
26143623
Links
Grant list
T32 AI007019 / AI / NIAID NIH HHS / United States